No Data
No Data
Market Cool On Enovis Corporation's (NYSE:ENOV) Revenues
You may think that with a price-to-sales (or "P/S") ratio of 1.4x Enovis Corporation (NYSE:ENOV) is a stock worth checking out, seeing as almost half of all the Medical Equipment companies in the
Enovis to Host Second Quarter 2024 Results Conference Call on August 7th
Wilmington, DE, July 16, 2024 (GLOBE NEWSWIRE) -- Enovis Corporation (NYSE:ENOV), an innovation-driven, medical technology growth company, announced that it will host an investor conference call and live
Enovis' (ENOV) New System to Aid Reverse Shoulder Prosthesis
Per a report by The Brainy Insights, the global shoulder arthroplasty market was estimated to be $1.52 billion in 2022 and is expected to reach $2.6 billion by 2030 at a growth rate of 6.9%.
Enovis Expands Shoulder Implant Offerings
Enovis (ENOV) said Friday it has expanded its AltiVate Reverse shoulder implants to include modular, augmented baseplates.The AltiVate Reverse glenoid system received US Food and Drug Administration
Express News | Enovis Releases AltiVate Reverse Glenoid System
Enovis Releases AltiVate Reverse Glenoid System, Widening Range of Patients Who May Be Treated With AltiVate Reverse
AUSTIN, TX, July 12, 2024 (GLOBE NEWSWIRE) -- Enovis (NYSE:ENOV), a leading innovator in shoulder arthroplasty systems that help improve quality of life and restore movement, introduced today the one-tray
No Data